Nivolumab and Ipilimumab in Mucinous Colorectal and Appendiceal Tumors
Status:
Completed
Trial end date:
2021-01-04
Target enrollment:
Participant gender:
Summary
This is a single-arm phase II study of twenty-one subjects with mucinous adenocarcinoma of
the colon, rectum, or appendix with prior systemic therapy with a fluoropyrimidine,
oxaliplatin, and irinotecan. Treatment will consist of nivolumab 480mg every 4 weeks and
ipilimumab 1mg/kg every 8 weeks until disease progression, unacceptable toxicity, or 2 years
of therapy.
Phase:
Phase 2
Details
Lead Sponsor:
Abramson Cancer Center of the University of Pennsylvania